Use of Sargramostim (rh-GM-CSF) as adjunctive treatment of fluconazole-refractory oropharyngeal candidiasis in patients with AIDS: A pilot study

HIV Clinical Trials

Volumn 1, Issue 3, 2000, Pages 23-29

  Vazquez, Jose A ^a,b   Hidalgo, Jose A ^a   Sharon De Bono, B S N ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

GM CSF; HIV; Oral candidiasis

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AIDS RELATED COMPLEX; ANTIBIOTIC RESISTANCE; ARTICLE; CANDIDA; CANDIDA ALBICANS; CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PILOT STUDY; THRUSH; TREATMENT OUTCOME;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; FEMALE; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0034329510     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/LF5T-WYY7-0U3E-G8BQ     Document Type: Article

References (18)

1. Vazquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy. 1999;19:76-87.
2. Coker RJ, Fisher M, Tomlinson DR. Management of mycoses associated with HIV disease. Int J STD AIDS. 1995;6:408-412.
3. Maenza JR, Keruly JC, Moore RD, et al. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. J Infect Dis. 1996;173:219-225.
4. Pitrak DL Neutrophil deficiency and dysfunction in HIV-infected patients. Am J Health Syst Pharm. 1999;56(suppl 5):S9-S20.
5. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis. 1995;171:1448-1454.
6. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1998;92:491-508.
7. Richardson MD, Brownlie CED, Shankland GS. Enhanced phagocytosis and intracellular killing of Candida albicans by GM-CSF-activated human neutrophils. J Med Vet Mycol. 1992;30:433-441.
8. Smith PD, Lamerson CL, Banks SM, et al. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J Infect Dis. 1990;161:999-1005.
9. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologus bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-1778.
10. Bodey GP, Anaissie E, Guterman J, et al. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy of fungal infection in patients with cancer. Clin Infect Dis. 1993;17:705-707.
11. Palau LA, Pankey GA. Resolution of rhinocerebral and disseminated mucormycosis with adjuvant administration of subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF). In: Proceedings of the 37th ICAAC; 1997; Toronto, Canada. Abstract LM-55.
12. Swindells S, Kleinschmidt DR, Hayes FA. Pilot study of adjunctive GM-CSF (yeast-derived) for fluconazole-resistant oral candidiasis in HIV-1 infection. Infect Dis Clin Pract. 1997;6:278-280.
13. Vazquez JA, Gupta S, Villanueva A. Potential utility of recombinant human GM-CSF as adjunctive treatment of refractory oropharyngeal candidiasis in AIDS patients. Eur J Clin Microbiol Infect Dis. 1998;17:781-783.
14. Angel JB, High K, Rhame F, et al. Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: Effect on infections, CD4 cell counts and HIV supression. AIDS. 2000;14:387-395.
15. Skowron G, Stein D, Drusano G, et al. The safety and efficacy of granulocyte-macrophage colony-stimulating factor (sargramostim) added to indinavir- or ritonavir-based antiretroviral therapy: A randomized double-blind, placebo-controlled trial. J Infect Dis. 1999;180:1064-1071.
16. National Committee for Clinical Laboratory Standards (NCCLS). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: Approved Standard. NCCLS document M27-A. Wayne, PA: NCCLS; 1997.
17. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis. 2000;30:662-669.
18. Powderly WG, Gallant JE, Ghannoum MA, et al. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy. AIDS Res Hum Retroviruses. 1999;15:1619-1623.